TITLE

Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses

AUTHOR(S)
Lawrence, Roger; Brown, Jillian R; Al-Mafraji, Kanar; Lamanna, William C; Beitel, James R; Boons, Geert-Jan; Esko, Jeffrey D; Crawford, Brett E
PUB. DATE
February 2012
SOURCE
Nature Chemical Biology;Feb2012, Vol. 8 Issue 2, p197
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
A considerable need exists for improved biomarkers for differential diagnosis, prognosis and monitoring of therapeutic interventions for mucopolysaccharidoses (MPS), inherited metabolic disorders that involve lysosomal storage of glycosaminoglycans. Here we report a simple, reliable method based on the detection of abundant nonreducing ends of the glycosaminoglycans that accumulate in cells, blood and urine of individuals with MPS. In this method, glycosaminoglycans are enzymatically depolymerized, releasing unique mono-, di- or trisaccharides from the nonreducing ends of the chains. The composition of the released mono- and oligosaccharides depends on the nature of the lysosomal enzyme deficiency, and therefore they serve as diagnostic biomarkers. Analysis by LC/MS allowed qualitative and quantitative assessment of the biomarkers in biological samples. We provide a simple conceptual scheme for diagnosing MPS in uncharacterized samples and a method to monitor efficacy of enzyme replacement therapy or other forms of treatment.
ACCESSION #
70392805

 

Related Articles

  • Mukopolysacharidóza I - klinické projevy u 24 dÄ•tí z ÄŒeské republiky a Slovenska. Ješina, P.; Magner, M.; Poupĕtová, H.; Honzíkova, J.; Dvořáková, L.; Malinová, V.; Hrubá, E.; Hlavatá, A.; Honzík, T.; Veselá, K.; Sedláček, P.; Starý, J.; Zeman, J. // Czecho-Slovak Pediatrics / Cesko-Slovenska Pediatrie;Jun2011, Vol. 66 Issue 4, p215 

    Mucopolysaccharidosis I (MPS I) is severe metabolic storage disease caused by impaired function of α-L-iduronidase. The aim of this study is to describe clinical symptoms, natural course and to evaluate results of treatment in Czech and Slovak children with MPS I. Methods: Study group...

  • Sleep disordered breathing in mucopolysaccharidosis I: a multivariate analysis of patient, therapeutic and metabolic correlators modifying long term clinical outcome. Pal, Abhijit Ricky; Langereis, Eveline J.; Saif, Muhammad A.; Mercer, Jean; Church, Heather J.; Tylee, Karen L.; Wynn, Robert F.; Wijburg, Frits A.; Jones, Simon A.; Bruce, Iain A.; Bigger, Brian W. // Orphanet Journal of Rare Diseases;Jun2015, Vol. 10 Issue 1, p1 

    Background: The lysosomal storage disorder, mucopolysaccharidosis I (MPS I), commonly manifests with upper airway obstruction and sleep disordered breathing (SDB). The success of current therapies, including haematopoietic stem cell transplantation (HSCT) and enzyme replacement therapy (ERT) may...

  • Muskuloskeletální postižení u pacientů s lyzozomálním střádavým onemocnÄ›ním. Májovská, J.; Malinová, V.; Dostálová, G.; Murgašová, L.; Poupětová, H.; Zeman, J.; Magner, M. // Czech Rheumatology / Ceska Revmatologie;2019, Vol. 27 Issue 4, p204 

    Lysosomal storage diseases (LSD) represent a heterogeneous group of > 60 severe hereditary metabolic disorders due to impaired function of one or more lysosomal enzymes or disorders of protein processing and transport across the lysosomal membrane. The diagnosis of LSD is based on clinical...

  • Impairment of glycosaminoglycan synthesis in mucopolysaccharidosis type IIIA cells by using siRNA: a potential therapeutic approach for Sanfilippo disease. Dziedzic, Dariusz; Węgrzyn, Grzegorz; Jakóbkiewicz-Banecka, Joanna // European Journal of Human Genetics;Feb2010, Vol. 18 Issue 2, p200 

    Mucopolysaccharidoses (MPS) are severe inherited metabolic disorders from the group of lysosomal storage diseases. They are caused by deficiency in the activity of enzymes involved in the degradation of glycosaminoglycans (GAGs) and resultant accumulation of these compounds in the cells of...

  • Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Wraith, J. Edmond; Scarpa, Maurizio; Beck, Michael; Bodamer, Olaf A.; De Meirleir, Linda; Guffon, Nathalie; Lund, Allan Meldgaard; Malm, Gunilla; Van der Ploeg, Ans T.; Zeman, Jiri // European Journal of Pediatrics;Mar2008, Vol. 167 Issue 3, p267 

    Mucopolysaccharidosis type II (MPS II; Hunter syndrome) is a rare X-linked recessive disease caused by deficiency of the lysosomal enzyme iduronate-2-sulphatase, leading to progressive accumulation of glycosaminoglycans in nearly all cell types, tissues and organs. Clinical manifestations...

  • Bone Mineral Density in Egyptian Children with Mucopolysaccharidoses. Koura, H. M.; EL-Katoury, A.; Abdallah, N. I.; EL-Bassyouni, H. T.; Ayoub, D. F.; Bassiouni, R. I. // Research Journal of Medicine & Medical Sciences;2009, Vol. 4 Issue 1, p100 

    The mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders caused by deficiency of enzymes catalyzing the degradation of glycosaminoglycans (GAGS). The MPS are rare diseases. MPS patients present with impaired growth, reduced walking capacity and lack of adequate nutrition, which...

  • Overview of the mucopolysaccharidoses. Muenzer, Joseph // Rheumatology;Dec2011 Supplement 5, Vol. 50 Issue suppl_5, pv4 

    The mucopolysaccharidoses (MPSs) are a group of rare, inherited lysosomal storage disorders that are clinically characterized by abnormalities in multiple organ systems and reduced life expectancy. The MPSs are heterogeneous, progressive disorders. Patients typically appear normal at birth, but...

  • Mucopolysaccharidoses type IV A (Morquio syndrome): A case series of three siblings. Rekka, P.; Rathna, P. V.; Jagadeesh, S.; Seshadri, S. // Journal of the Indian Society of Pedodontics & Preventive Dentis;Jan-Mar2012, Vol. 30 Issue 1, p66 

    Mucopolysaccharidoses (MPS) are a family of inherited metabolic diseases that results from the deficiency of lysosomal enzymes involved in the degradation of the glycosaminoglycans (mucopolysaccharides). Despite the well-documented oral and dental findings of MPS type IV, there is not much...

  • chondro-osteodystrophy.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p442 

    An encyclopedia entry for "chondro-osteodystrophy," which pertains to mucopolysaccharidosis, is presented.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics